Gilead Sciences has completed its acquisition of Arcellx in a deal valued at approximately $7.8 billion.

Anito-cel is a BCMA-directed CAR T-cell therapy that uses a D-domain binder. This design aims to improve CAR expression while reducing unwanted immune activity. The therapy is being developed to target multiple myeloma cells effectively while limiting severe immune-related side effects. It has received Fast Track, Orphan Drug and Regenerative Medicine Advanced Therapy designations from the US Food and Drug Administration.

The acquisition gives Gilead full ownership of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy targeting BCMA for the treatment of multiple myeloma. The move also removes future obligations related to profit-sharing, milestones and royalties, allowing the company to streamline development and decision-making.

The deal builds on the existing collaboration between Kite, a Gilead company, and Arcellx. With full control, Gilead plans to advance anito-cel using its global manufacturing, regulatory and commercial infrastructure.

Gilead completed its tender offer for Arcellx shares, securing around 77.2 per cent of the company’s outstanding stock, including shares already owned. The acquisition was finalised through a merger, making Arcellx a wholly owned subsidiary. Its shares will be delisted from the Nasdaq Global Select Market.

The CVR is linked to the commercial performance of anito-cel and will be payable if the therapy reaches at least $6 billion in cumulative global net sales by the end of 2029.

Gilead expects the transaction to be treated as an asset acquisition. It anticipates a reduction in both GAAP and non-GAAP diluted earnings per share for 2026 by approximately $5.57 to $5.67. Excluding acquired in-process research and development costs, the deal is expected to have a modest negative impact on earnings in 2026 and 2027, with potential gains from 2028 onwards, subject to regulatory approval.

 

Source: gilead.com

Report Abuse